Last checked at 
(Alliance News) - Indivior PLC on Wednesday posted results from its two-year analysis of opioid users enrolled in its RECOVER study.
The RECOVER study examines long-term recovery in individuals with moderate to severe opioid use disorder following their transition from two Phase 3 clinical trials of Indivior's Sublocade injection into a real-world setting.
The drug manufacturer said of the 533 participants who enrolled in the study, 396 completed the 24-month assessment. A total of 218 individuals - or 44% of those contributing data - reported sustained illicit opioid-free weeks for the entire period. Nearly half of the participants were employed over the two years, with percentages increasing from 35% at pre-trial screening to between 45% to 48% at 24 months.
Indivior said that, over the two-year period, 15% of participants reported staying overnight in a hospital and 12% reported having an emergency department visit. Among the 495 participants who contributed data, 69% received substance use disorder treatment, with buprenorphine medication assisted treatment being the most prevalent.
"Opioid use disorder is a chronic disease and its treatment is complex and multifaceted. These findings show that long-term treatment with counseling may positively assist patients in focusing on their recovery, including discontinuation of illicit opioid use. Over the 24-month RECOVER observation period, participants also achieved and maintained positive effects including improved employment rates and lower healthcare system utilization," said Walter Ling, research professor in the department of family medicine, at the David Geffen School of Medicine, UCLA.
The next phase of the RECOVER study will seek to provide further information to health care systems and policymakers on how continuity of care can help address opioid abuse, Indivior said.
Indivior shares were trading 0.3% lower at 76.35 pence each on Wednesday afternoon in London, but 93% higher than at the start of the year.
By Ife Taiwo; ifetaiwo@alliancenews.com.
Copyright 2020 Alliance News Limited. All Rights Reserved.
